Viktor Alexandrovich Gritsenko

Viktor Alexandrovich Gritsenko

Auto-generated profile, based on publicly available information

Viktor Alexandrovich Gritsenko

Orenburg Federal Research Center, Ural Branch of the Russian Academy of Sciences (Institute of Cellular and Intracellular Symbiosis, Ural Branch of the Russian Academy of Sciences)

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Environmental Pollution
Verified
Journal Article
Closed access
TATinkov Alexey
Tinkov Alexey
VGViktor A. Gritsenko
Viktor A. Gritsenko
MSMargarita G. Skalnaya
Margarita G. Skalnaya
SCSergey V. Cherkasov
Sergey V. Cherkasov
Jan O. AasethJan O. Aaseth
Jan O. Aaseth
ASAnatoly Skalny
Anatoly Skalny

7 September 2009 in International Journal of Andrology
Verified
Journal Article
Closed access
IIIuri B. Ivanov
Iuri B. Ivanov
MKMichael D. Kuzmin
Michael D. Kuzmin
VGViktor A. Gritsenko
Viktor A. Gritsenko

28 September 2013 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
TATinkov Alexey
Tinkov Alexey
ONOlga N. Nemereshina
Olga N. Nemereshina
EPElizaveta V. Popova
Elizaveta V. Popova
VPValentina S. Polyakova
Valentina S. Polyakova
VGViktor A. Gritsenko
Viktor A. Gritsenko
Alexandr NikonorovAlexandr Nikonorov
Alexandr Nikonorov

17 November 2021 in Medical Immunology (Russia)
Verified
Journal Article
Open access
PDF file
AZAleksandr Zurochka
Aleksandr Zurochka
VZVladimir Zurochka
Vladimir Zurochka
MDM. A. Dobrynina
M. A. Dobrynina
VGV. A. Gritsenko
V. A. Gritsenko
Granulocyte-macrophage colony-stimulating factor (GM-CSF) belongs to the group of growth cytokines (hematopoietins) that regulate proliferation and differentiation of myeloid lineage cells. Recently, a lot of new data have accumulated, indicating the presence of a number of previously unknown biological effects in GM-CSF and synthetic peptides of its active center, which open up new prospects for their wide clinical use.The review outlines current understanding of the structure, functions, and mechanisms of GM-CSF action and concerns the structure of its receptor. The GM-CSF producer cells are characterized, as well as target cells (effector cells) responding to this cytokine are also presented. The known mechanisms of intracellular signaling involved into the GM-CSF/receptor interaction are described. The main pleiotropic effects of this cytokine as a factor of hematopoiesis and an immunostimulating agent are characterized. The previously known and recently found immunobiological effects of this cytokine, its recombinant forms and synthetic analogues of its active center are discussed.Participation of GM-CSF in hematopoiesis and differentiation of myeloid cells, the effects of this cytokine on the functional activity of immunocompetent populations (lymphocytes, macrophages, neutrophils, dendritic cells) and tissue cells were characterized. The influence of GM-CSF on the development and course of infectious and inflammatory processes, its role in the creation of combined vaccines is reviewed. Clinical data on usage of GM-CSF and its recombinant forms in hematology, immunology, oncology, reproductive medicine and in the treatment of systemic autoimmune processes and infectious diseases are presented.The recently discovered immunobiological properties of synthetic peptides derived from active center of GM-CSF are summarized, indicating that they exhibit immunotropic and hematopoietic effects, as well as antimicrobial activity against Gram-negative and Gram-positive bacteria, viruses, and tissue repair (effect on the rate of wound healing), which is not typical to the whole GM-CSF molecule. We discuss the prospects for clinical applications of synthetic GM-CSF analogue (ZP2 peptide), and an opportunity of creating new cosmetics and pharmaceuticals with combined immunostimulating, antimicrobial and reparative properties on its basis.The review expands the view on potential usage of cytokine therapy in the treatment of various infectious and non-infectious diseases in humans, and is addressing a wide range of specialists working in the field of allergology and immunology, infectology and regenerative medicine.

1 December 2006 in Journal of Medical Microbiology
Verified
Journal Article
Open access
PDF file
IIIuri B. Ivanov
Iuri B. Ivanov
VGViktor A. Gritsenko
Viktor A. Gritsenko
MKMichael D. Kuzmin
Michael D. Kuzmin
This study reports the detection of an extracellular staphylococcal product, designated secretory inhibitor of platelet microbicidal protein (SIPMP), that causes local inhibition of the bactericidal action of platelet microbicidal protein (PMP) in the fluid phase. Urethral isolates of Staphylococcus aureus (n=24) and coagulase-negative staphylococci (CNS) (n=47) from patients with or without chronic bacterial prostatitis (CBP) were tested. SIPMP production was tested by inhibition of PMP bioactivity against Bacillus subtilis and was expressed as percentage inhibition of PMP bactericidal activity. The PMP susceptibility of staphylococcal strains was determined by exposing bacterial cells to serial dilutions of PMP. Staphylococci from patients without CBP produced SIPMP at levels of 10.3±1.2 and 13.25±1.72 % for S. aureus and CNS, respectively. Strains isolated from men with CBP inhibited PMP-induced killing of B. subtilis by 23.38±4.2 % (P<0.05) and 23.69±1.87 % (P<0.01) for S. aureus and CNS, respectively. SIPMP production correlated with staphylococcal resistance to PMP (r 2=0.6082 and 0.7264 for S. aureus and CNS, respectively). SIPMP represents a hitherto unrecognized determinant of staphylococcal pathogenicity. These results suggest that SIPMP production is associated with the CBP source. Data from this study may have significant implications for the understanding of the pathogenesis of CBP.

21 October 2014 in Pharmaceutical Biology
Verified
Journal Article
Closed access
PDF file
ONOlga N. Nemereshina
Olga N. Nemereshina
TATinkov Alexey
Tinkov Alexey
VGViktor A. Gritsenko
Viktor A. Gritsenko
Alexandr NikonorovAlexandr Nikonorov
Alexandr Nikonorov
Context: The data concerning the influence of Plantaginaceae water extracts on bacterial growth are contradictory. Objective: This study investigates the influence of Plantago maxima Juss. ex Jacq., Plantago lanceolata L., Plantago major L., Veronica teucrium L., Veronica spicata L., and Veronica incana L. aqueous extracts on growth of Escherichia coli K12 culture and the relation to antioxidant, reducing, and iron-binding activities. Materials and methods: Aqueous extracts were prepared from the dried leaves with the final concentration of 1/10, 1/15, 1/20, 1/25, 1/30, 1/35, and 1/40 (w/w). Comparative analysis of total flavonoids, iridoids, and tannins in Plantaginaceae species was performed. Iron-binding, antioxidant, and reducing activities of plant extracts were analyzed spectrophotometrically. The influence of plant extracts on E. coli K12 growth was studied in vitro by estimating the bacterial growth in the extract-containing medium. Results: Total tannin content in plant leaves positively correlated with iron-binding activity (r = 0.641), whereas total flavonoids correlated with antioxidant activity (r = 0.687). In an in vitro model, it is estimated that water extracts of studied Plantaginaceae species stimulated bacterial growth. Prebiotic activity significantly of 1/20 and 1/40 plant extracts positively correlated with antioxidant (r = 0.589; r = 0.576, respectively) and reducing activity (r = 0.721; r = 0.620, respectively) of plant aqueous extracts at 6–24 h. Negative correlation was observed between iron-binding activity and bacterial growth (r = −0.503 and r = −0.534 for 1/20 and 1/40 extracts, respectively). Conclusion: Aqueous Plantaginaceae extracts possess prebiotic activity depending on the phytochemical content of plant leaves.